MedTrace Logo

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

NCT06902844 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-03-30

No results posted yet for this study

Summary

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Lupus Nephritis (LN)

Interventions

DRUG

Equecabtagene Autoleucel Injection

dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.

Sponsors & Collaborators

  • Nanjing IASO Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • Tongji Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-05
Primary Completion
2027-10-31
Completion
2028-01-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06902844 on ClinicalTrials.gov